Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

6 treatments under study, led by Losartan

Research Leaders

11 sponsors active, led by Cairo University

Related Conditions

Often studied with 13 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
Phase 2 (1)
Phase 3 (1)

Trial Status

Completed2
Recruiting1
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT05619653Phase 3Active Not Recruiting

Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19

NCT07169981Phase 2Completed

Effect of Empagliflozin 10 vs 25 mg on LV Remodeling in Diabetic Patients With Anterior STEMI With Reduced LVEF

NCT06662890Not ApplicableRecruiting

Heart Attack Blood Oxygen Therapy Trial

NCT04773652Completed

Predictors of Adverse Left Ventricular Remodeling and Final Infarct Size After Primary Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction: A Strain Analysis Study Using Echocardiography and Feature Tracking Cardiac Magnetic Resonance

Showing all 4 trials

Research Network

Common Treatments

  • Losartan1
  • Supersaturated Oxygen1
  • Sham No Treatment1
  • Empagliflozin1
  • Prednisolone1

Active Sponsors

  • Cairo University1
  • Ain Shams University1
  • Aswan Heart Centre1
  • Bayer1
  • Goethe University Frankfurt1

Top Investigators

Related Conditions

  • Myocardial Infarct1
  • Myocarditis Pericarditis1
  • Long Covid1
  • Remodeling Vascular1
  • Microvascular Angina1

Activity Timeline